| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
RESPIRATORY INFECTION |
1 Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong
2 Department of Anesthesia and Intensive Care, The Chinese University of Hong Kong, Hong Kong
3 Department of Microbiology, The University of Hong Kong, Hong Kong
4 Department of Microbiology, The Chinese University of Hong Kong, Hong Kong
5 Department of Diagnostic Radiology and Organ Imaging, The Chinese University of Hong Kong, Hong Kong
6 Center for Clinical Trial and Epidemiological Research, The Chinese University of Hong Kong, Hong Kong
Correspondence to:
Correspondence to:
Dr D S C Hui
Department of Medicine and Therapeutics, Prince of Wales Hospital, Shatin, NT, Hong Kong; dschui{at}cuhk.edu.hk
Background: The outcome is reported of a prospective uncontrolled study based on a stepwise treatment protocol during an outbreak of severe acute respiratory syndrome (SARS) in Hong Kong.
Method: One hundred and thirty eight patients were treated with broad spectrum antibiotics, a combination of ribavirin and low dose corticosteroid, and then intravenous high dose methylprednisolone according to responses. Sustained response to treatment was defined as (1) defervescence for 
4 consecutive days, (2) resolution of lung consolidation by >25%, and (3) oxygen independence by the fourth day without fever. Patients with defervescence who achieved either criterion 2 or 3 were classified as partial responders. Patients who fell short of criteria 2 and 3 were non-responders.
Results: Laboratory confirmation of SARS coronavirus infection was established in 132 (95.7%). None responded to antibiotics but 25 (18.1%) responded to ribavirin + low dose corticosteroid. Methylprednisolone was used in 107 patients, of whom 95 (88.8%) responded favourably. Evidence of haemolytic anaemia was observed in 49 (36%). A high level of C-reactive protein at presentation was the only independent predictor for use of methylprednisolone (odds ratio 2.18 per 10 mg/dl increase, 95% confidence interval 1.12 to 4.25, p = 0.02). Thirty seven patients (26.8%) required admission to the intensive care unit and 21 (15.2%) required invasive mechanical ventilation. There were 15 deaths (mortality rate 10.9%), most with significant co-morbidities, whereas 122 (88.4%) had been discharged home 4 months after the outbreak onset.
Conclusion: The use of high dose pulse methylprednisolone during the clinical course of a SARS outbreak was associated with clinical improvement, but randomised controlled trials are needed to ascertain its efficacy in this condition.
Keywords: severe acute respiratory syndrome (SARS); ribavirin; treatment; corticosteroid; outcome
Relevant Article
Thorax 2004 59: 361.
This article has been cited by other articles:
|
|
 |
|
  H Li, N L-S Tang, P K-S Chan, C-Y Wang, D S-C Hui, C Luk, R Kwok, W Huang, J J-Y Sung, Q-P Kong, et al. Polymorphisms in the C-type lectin genes cluster in chromosome 19 and predisposition to severe acute respiratory syndrome coronavirus (SARS-CoV) infection J. Med. Genet., November 1, 2008; 45(11): 752 - 758. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Y. Wong and K.-Y. Yuen The management of coronavirus infections with particular reference to SARS J. Antimicrob. Chemother., September 1, 2008; 62(3): 437 - 441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Lee, M. Ip, B. Wong, G. Lui, O. T. Y. Tsang, J. Y. Lai, K. W. Choi, R. Lam, T. K. Ng, J. Ho, et al. Risk Factors Associated with Life-threatening Rickettsial Infections Am J Trop Med Hyg, June 1, 2008; 78(6): 973 - 978. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. G. Nichols, A. J. Peck Campbell, and M. Boeckh Respiratory Viruses Other than Influenza Virus: Impact and Therapeutic Advances Clin. Microbiol. Rev., April 1, 2008; 21(2): 274 - 290. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. C. C. Cheng, S. K. P. Lau, P. C. Y. Woo, and K. Y. Yuen Severe Acute Respiratory Syndrome Coronavirus as an Agent of Emerging and Reemerging Infection Clin. Microbiol. Rev., October 1, 2007; 20(4): 660 - 694. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. E. Severson, N. Shindo, M. Sosa, T. Fletcher III, E. L. White, S. Ananthan, and C. B. Jonsson Development and Validation of a High-Throughput Screen for Inhibitors of SARS CoV and Its Application in Screening of a 100,000-Compound Library J Biomol Screen, February 1, 2007; 12(1): 33 - 40. [Abstract] [PDF]
|
|
|
|
 |
|
 R.-c. Chen, X.-p. Tang, S.-y. Tan, B.-l. Liang, Z.-y. Wan, J.-q. Fang, and N. Zhong Treatment of Severe Acute Respiratory Syndrome With Glucosteroids: The Guangzhou Experience Chest, June 1, 2006; 129(6): 1441 - 1452. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. L.-S. Tang, P. K.-S. Chan, C.-K. Wong, K.-F. To, A. K.-L. Wu, Y.-M. Sung, D. S.-C. Hui, J. J.-Y. Sung, and C. W.-K. Lam Early Enhanced Expression of Interferon-Inducible Protein-10 (CXCL-10) and Other Chemokines Predicts Adverse Outcome in Severe Acute Respiratory Syndrome Clin. Chem., December 1, 2005; 51(12): 2333 - 2340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Hui, K. T. Wong, F. W. Ko, L. S. Tam, D. P. Chan, J. Woo, and J. J.Y. Sung The 1-Year Impact of Severe Acute Respiratory Syndrome on Pulmonary Function, Exercise Capacity, and Quality of Life in a Cohort of Survivors Chest, October 1, 2005; 128(4): 2247 - 2261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Ghani, C. A. Donnelly, D. R. Cox, J. T. Griffin, C. Fraser, T. H. Lam, L. M. Ho, W. S. Chan, R. M. Anderson, A. J. Hedley, et al. Methods for Estimating the Case Fatality Ratio for a Novel, Emerging Infectious Disease Am. J. Epidemiol., September 1, 2005; 162(5): 479 - 486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D S Hui, G M Joynt, K T Wong, C D Gomersall, T S Li, G Antonio, F W Ko, M C Chan, D P Chan, M W Tong, et al. Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors Thorax, May 1, 2005; 60(5): 401 - 409. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. E. Antonio, K. T. Wong, E. L. H. Tsui, D. P. N. Chan, D. S. C. Hui, A. W. H. Ng, K. K. Shing, E. H. Y. Yuen, J. C. K. Chan, and A. T. Ahuja Chest Radiograph Scores as Potential Prognostic Indicators in Severe Acute Respiratory Syndrome (SARS) Am. J. Roentgenol., March 1, 2005; 184(3): 734 - 741. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.W. Tsang, G.C. Ooi, and P.L. Ho Diagnosis and pharmacotherapy of severe acute respiratory syndrome: what have we learnt? Eur. Respir. J., December 1, 2004; 24(6): 1025 - 1032. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S.C. Hui and J. J.Y. Sung Treatment of Severe Acute Respiratory Syndrome Chest, September 1, 2004; 126(3): 670 - 674. [Full Text] [PDF]
|
|
|
|
|
|
W C Yu, D S C Hui, and M Chan-Yeung Antiviral agents and corticosteroids in the treatment of severe acute respiratory syndrome (SARS) Thorax, August 1, 2004; 59(8): 643 - 645. [Full Text] [PDF]
|
|
|
|
 |
|
 D S C Hui, M C H Chan, A K Wu, and P C Ng Severe acute respiratory syndrome (SARS): epidemiology and clinical features Postgrad. Med. J., July 1, 2004; 80(945): 373 - 381. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
